Modality
ADC
MOA
BTKi
Target
AuroraA
Pathway
RNA Splicing
FabryEpilepsy
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Apr 2029
Phase 1Current
NCT08132646
955 pts·Fabry
2019-04→2026-03·Not yet recruiting
NCT04580950
93 pts·Epilepsy
2017-10→2029-04·Not yet recruiting
1,048 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-274d agoPh2 Data· Fabry
2029-04-263.1y awayPh2 Data· Epilepsy
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2026-03-27 · 4d ago
Fabry
Ph2 Data
2029-04-26 · 3.1y away
Epilepsy
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08132646 | Phase 1/2 | Fabry | Not yet recr... | 955 | EASI-75 |
| NCT04580950 | Phase 1/2 | Epilepsy | Not yet recr... | 93 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |